Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets
- PMID: 20025563
- DOI: 10.2174/138620709789824736
Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets
Abstract
Low molecular weight inhibitors of Protein-Protein Interactions (PPI's) have been identified for a number of different systems indicating the viability of the computer-aided drug design approaches. However, pathways undertaken by researchers in pharmaceutical companies or in academic laboratories are not always clearly defined and the protocols that allow the identification of lead compounds often remain blurry. We will enumerate in this review the main approaches carried out to identify and validate PPI's inhibitors. Emphasis will be placed, in a first part, on issues of particular significance to PPI's such as the problem of identification and validation of interacting sites and on the methods that allow assessing the 3D structure of a targeted complex. On the second part of this review, we will define approaches that allow a rapid identification of hits capable of inhibiting PPI's. We will highlight the problem of the scoring functions and demonstrate that the majority of the functions available to researchers are not especially relevant for PPI's. We will define why consensus scoring can be an alternative and we will propose GFscore, a non linear ranked-by number consensus scoring function as a solution to this problem. We will finally discuss the actual challenges that still remain, particularly the problem of the treatment of the receptor flexibility and of the water molecules at the interface of the Protein-Protein complexes.
Similar articles
-
Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database.PLoS One. 2010 Mar 9;5(3):e9598. doi: 10.1371/journal.pone.0009598. PLoS One. 2010. PMID: 20231898 Free PMC article.
-
Importance of molecular computer modeling in anticancer drug development.J BUON. 2007 Sep;12 Suppl 1:S101-18. J BUON. 2007. PMID: 17935268 Review.
-
Scoring functions for prediction of protein-ligand interactions.Curr Pharm Des. 2013;19(12):2174-82. doi: 10.2174/1381612811319120005. Curr Pharm Des. 2013. PMID: 23016847 Review.
-
Consensus scoring for protein-ligand interactions.Drug Discov Today. 2006 May;11(9-10):421-8. doi: 10.1016/j.drudis.2006.03.009. Drug Discov Today. 2006. PMID: 16635804 Review.
-
Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I).Curr Opin Chem Biol. 2011 Aug;15(4):475-81. doi: 10.1016/j.cbpa.2011.05.024. Epub 2011 Jun 22. Curr Opin Chem Biol. 2011. PMID: 21684802 Review.
Cited by
-
Small molecule inhibitors of hantavirus infection.Bioorg Med Chem Lett. 2010 Dec 1;20(23):7085-91. doi: 10.1016/j.bmcl.2010.09.092. Epub 2010 Sep 19. Bioorg Med Chem Lett. 2010. PMID: 20951038 Free PMC article.
-
Bound water at protein-protein interfaces: partners, roles and hydrophobic bubbles as a conserved motif.PLoS One. 2011;6(9):e24712. doi: 10.1371/journal.pone.0024712. Epub 2011 Sep 22. PLoS One. 2011. PMID: 21961043 Free PMC article.
-
Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.ACS Med Chem Lett. 2011 May 12;2(5):337-341. doi: 10.1021/ml1002579. ACS Med Chem Lett. 2011. PMID: 21643473 Free PMC article.
-
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.Oncotarget. 2013 Oct;4(10):1632-46. doi: 10.18632/oncotarget.1365. Oncotarget. 2013. PMID: 24142503 Free PMC article.
-
β-Hairpin Peptidomimetics for Protein-Protein Interaction Inhibition.Methods Mol Biol. 2025;2934:41-56. doi: 10.1007/978-1-0716-4578-9_4. Methods Mol Biol. 2025. PMID: 40663322
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources